Alliqua BioMedical (ADYX) Stock Price, News & Analysis

Company Overview

Alliqua BioMedical, Inc. is a medical technology company focused on the development, manufacture and commercialization of advanced therapeutic products for acute and chronic wound care and tissue regeneration. Its core product portfolio includes proprietary amniotic membrane allografts processed to preserve growth factors, cytokines and extracellular matrix proteins, as well as collagen-based dressings and other bioactive formulations designed to support tissue repair, reduce inflammation and promote healing in complex wounds.

Headquartered in College Station, Texas, Alliqua markets its products primarily across the United States through a combination of direct sales and distribution partnerships with hospitals, wound care centers and physician practices. The company operates manufacturing facilities that comply with FDA regulations and industry standards for tissue handling and medical device production. Alliqua’s commercial infrastructure serves both inpatient and outpatient settings with an emphasis on expanding access to advanced wound care therapies.

In recent years, Alliqua has enhanced its regenerative medicine capabilities through targeted acquisitions and internal product development. By integrating new tissue platforms and refining its processing technologies, the company aims to address diverse clinical needs in areas such as dermatology, orthopedics and surgical repair. Continued investment in research and development supports Alliqua’s goal of delivering next-generation solutions that improve patient outcomes and advance the practice of therapeutic tissue regeneration.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0002
• Volume: 353 shs
• Average Volume: 353 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ADYX
• CIK: 1054274
• Web: www.adynxx.com
• Phone: (415) 512-7740
• Fax: 215-702-8535
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A